Summit Therapeutics Inc. (BMV:SMMT)
Mexico · Delayed Price · Currency is MXN | Market Cap | 182.94B -49.7% |
| Revenue (ttm) | n/a |
| Net Income | -21.74B |
| EPS | -28.72 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,500 |
| Open | 290.12 |
| Previous Close | 407.58 |
| Day's Range | 290.12 - 290.12 |
| 52-Week Range | 281.00 - 430.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 23, 2026 |
About Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto... [Read more]
News
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progres...
Summit Therapeutics signs agreement to sell ridinilazole to Biossil
Summit Therapeutics (SMMT) signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificia...
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational P...
Summit Therapeutics withdraws proposed underwritten public offering
In a regulatory filing, Summit Therapeutics (SMMT) announced that effective June 10, 2026 it has withdrawn its previously announced proposed underwritten public offering of securities due to market co...
Summit Therapeutics falls -10.2%
Summit Therapeutics (SMMT) is down -10.2%, or -$1.46 to $12.83.
Summit Therapeutics put volume heavy and directionally bearish
Bearish flow noted in Summit Therapeutics (SMMT) with 1,656 puts trading, or 1.2x expected. Most active are 6/12 weekly 13 puts and Jul-26 13 puts, with total volume in those…
Summit Therapeutics Transcript: AGM 2026
The meeting covered board elections, auditor ratification, executive compensation, and a stock plan amendment, all of which were approved by shareholders. No questions were raised during the Q&A session.
Summit Therapeutics announces $500M common stock offering
Summit Therapeutics (SMMT) announced that it has commenced an underwritten public offering of $500M of shares of its common stock. All of the shares in the proposed offering are being…
Summit Therapeutics Announces Proposed Public Offering of Common Stock
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has commenced an underwritten public offering of $500.0 million of ...
Summit Therapeutics files automatic mixed securities shelf
16:34 EDT Summit Therapeutics (SMMT) files automatic mixed securities shelf
Summit Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Ivonescimab is advancing as a leading PD-1/VEGF bispecific, with strong phase III data showing significant survival benefits over standard therapies. Multiple pivotal trials are progressing ahead of schedule, supported by robust financials and a broad development pipeline.
The Era of the One-Size-Fits-All Cancer Drug Is Ending
Investors have bet new drugs can topple Merck's Keytruda, but the evidence so far points to something smaller.
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami...
An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
Summit Therapeutics Transcript: Status update
Ivonescimab plus chemotherapy demonstrated a significant overall survival benefit in advanced squamous NSCLC in the HARMONi-6 phase III trial, with consistent efficacy across all PD-L1 subgroups and a favorable safety profile. Ongoing global trials and regulatory filings position ivonescimab as a potential new standard of care and blockbuster therapy.
Summit Therapeutics Press release: Status update
Summit Therapeutics issued a press release on June 1, 2026, disclosing material business information to investors.
Summit Therapeutics Slides: Status update
Summit Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines' ...
Summit Therapeutics announces OS results from Phase 3 HARMONi-6 trial
Summit Therapeutics (SMMT) announced overall survival, OS, results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit’s partner Akeso, will be presented as part of the…
Summit Therapeutics presents new results from AK112-206 trial
Summit Therapeutics (SMMT) presented new results from the AK112-206 trial, a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer co-sponsored by Summit and Akeso,...
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by...
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of...
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-...
Summit Therapeutics management to meet with Cantor
Breakfast Meeting with Management to be held in Chicago on June 2 hosted by Cantor.
Summit Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Summit Therapeutics (SMMT) to Neutral from Buy without a price target The firm is concerned by the continued absence of a more mature HARMONi-2 OS update. Without…